Bruker Co. (NASDAQ:BRKR) Shares Purchased by Xponance Inc.

Xponance Inc. boosted its stake in Bruker Co. (NASDAQ:BRKR) by 2.7% during the 4th quarter, HoldingsChannel reports. The fund owned 21,931 shares of the medical research company’s stock after buying an additional 569 shares during the period. Xponance Inc.’s holdings in Bruker were worth $1,286,000 as of its most recent SEC filing.

Several other institutional investors have also recently added to or reduced their stakes in the stock. Natixis Advisors LLC raised its holdings in Bruker by 145.8% in the fourth quarter. Natixis Advisors LLC now owns 360,631 shares of the medical research company’s stock valued at $21,140,000 after acquiring an additional 213,937 shares in the last quarter. Impact Capital Partners LLC acquired a new stake in shares of Bruker during the fourth quarter worth $203,000. Swiss National Bank raised its holdings in shares of Bruker by 0.8% during the fourth quarter. Swiss National Bank now owns 208,500 shares of the medical research company’s stock worth $12,222,000 after purchasing an additional 1,600 shares during the period. EverSource Wealth Advisors LLC raised its holdings in shares of Bruker by 41.5% during the fourth quarter. EverSource Wealth Advisors LLC now owns 1,330 shares of the medical research company’s stock worth $78,000 after purchasing an additional 390 shares during the period. Finally, Sequoia Financial Advisors LLC raised its holdings in shares of Bruker by 15.9% during the fourth quarter. Sequoia Financial Advisors LLC now owns 39,599 shares of the medical research company’s stock worth $2,321,000 after purchasing an additional 5,427 shares during the period. 79.52% of the stock is owned by institutional investors and hedge funds.

Bruker Stock Performance

Shares of BRKR opened at $44.45 on Friday. The firm has a 50-day moving average price of $52.16 and a 200 day moving average price of $57.69. The firm has a market capitalization of $6.74 billion, a PE ratio of 58.49, a P/E/G ratio of 2.16 and a beta of 1.18. The company has a quick ratio of 0.77, a current ratio of 1.60 and a debt-to-equity ratio of 1.15. Bruker Co. has a 52-week low of $43.51 and a 52-week high of $94.64.

Bruker (NASDAQ:BRKR) last announced its earnings results on Thursday, February 13th. The medical research company reported $0.76 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.75 by $0.01. Bruker had a net margin of 3.36% and a return on equity of 21.01%. On average, sell-side analysts anticipate that Bruker Co. will post 2.69 earnings per share for the current fiscal year.

Bruker Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, March 28th. Stockholders of record on Monday, March 17th will be given a dividend of $0.05 per share. The ex-dividend date of this dividend is Monday, March 17th. This represents a $0.20 annualized dividend and a dividend yield of 0.45%. Bruker’s dividend payout ratio (DPR) is 26.32%.

Analyst Ratings Changes

A number of analysts have weighed in on the stock. Bank of America increased their target price on shares of Bruker from $78.00 to $80.00 and gave the stock a “buy” rating in a report on Friday, December 13th. Stifel Nicolaus dropped their target price on shares of Bruker from $70.00 to $57.00 and set a “hold” rating on the stock in a report on Friday, February 14th. The Goldman Sachs Group raised shares of Bruker from a “sell” rating to a “neutral” rating and set a $60.00 target price on the stock in a report on Thursday, December 5th. Guggenheim restated a “buy” rating on shares of Bruker in a research report on Monday, February 24th. Finally, Barclays lowered their price target on shares of Bruker from $69.00 to $65.00 and set an “overweight” rating for the company in a research report on Monday, February 10th. Six investment analysts have rated the stock with a hold rating and six have issued a buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $70.50.

Bruker Profile

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.